Current Report Filing (8-k)
January 20 2017 - 4:24PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
January 19, 2017
AMEDICA
CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-33624
|
|
84-1375299
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1885
West 2100 South
Salt
Lake City, UT 84119
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code:
(801) 839-3500
N/A
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.01
|
Entry
into a Material Definitive Agreement.
|
On
January 19, 2017, Amedica Corporation (the “Company” or “Amedica”) entered into an Underwriting Agreement
(the “Underwriting Agreement”) with Maxim Group LLC, as representative of the underwriters identified therein (collectively,
the “Underwriters”), pursuant to which the Company agreed to issue and sell 8,900,000 shares (the “Shares”)
of common stock, $0.01 par value per share (the “Common Stock”) and warrants (the “Warrants”) to purchase
4,005,000 shares of Common Stock (the “Warrant Shares”), at a public offering price of $0.51 per Share
and 0.45 Warrants (the “Offering”). Each whole Warrant is exercisable for one share of Common Stock.
Amedica expects to receive approximately $3.7 million in net proceeds from the Offering, after deducting underwriting
discounts and commissions and estimated offering expenses.
Under
the terms of the Underwriting Agreement, the Company has granted the Underwriters a 45-day option to purchase up to an additional
15% of the shares of Common Stock plus up to 15% of the Warrants (provided that in no event may the aggregate market value of
securities sold in the offering, including from the over-allotment option, exceed the limitations set forth in Rule I.B.6 of Form
S-3), solely to cover over-allotments, if any.
The
Warrants to be issued in the Offering will be exercisable beginning on the closing date and expire on the five year anniversary
of the closing date and have an initial exercise price per share equal to $0.55 per share, subject to appropriate adjustment
in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations
or similar events affecting the Company’s Common Stock.
The
Shares and Warrants are being offered and sold pursuant to the Company’s effective registration statement on Form S-3 (Registration
No. 333-205545), which was declared effective by the Securities Exchange Commission (the “SEC”) on July 20, 2015,
and the base prospectus included therein, as amended and supplemented by the preliminary prospectus supplement filed with the
SEC on January 18, 2017, and the final prospectus supplement filed with the SEC on January 19, 2017. The Offering is expected
to close on or about January 24, 2017, subject to satisfaction of customary closing conditions.
The
above descriptions of the Underwriting Agreement and Warrants are qualified in their entirety by the Underwriting Agreement and
Form of Warrant, which are attached to this report as Exhibit 1.1 and Exhibit 4.1, respectively, and which are incorporated by
reference into the Registration Statement.
In
connection with the Offering, Amedica is filing a legal opinion and consent as Exhibit 5.1 and Exhibit 23.1 to this report, which
are incorporated by reference into the Registration Statement. In addition, on January 19, 2017, Amedica issued a press release
announcing that it had priced the Offering, which press release is filed as Exhibit 99.1 to this report and is incorporated herein
by reference.
Item
9.01
|
Financial
Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
1.1*
|
|
Underwriting
Agreement, dated as of January 19, 2017, by and between Amedica Corporation and Maxim Group LLC
|
|
|
|
4.1*
|
|
Form
of Warrant
|
|
|
|
5.1*
|
|
Opinion
of Dorsey & Whitney LLP
|
|
|
|
23.1*
|
|
Consent
of Dorsey & Whitney LLP (included in Exhibit 5.1)
|
|
|
|
99.1*
|
|
Press
Release dated January 19, 2017
|
*
Filed herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
AMEDICA
CORPORATION
|
|
|
|
|
|
Date:
|
January
20, 2017
|
|
By:
|
/s/
B. Sonny Bal
|
|
|
|
|
B.
Sonny Bal
|
|
|
|
|
Chief
Executive Officer
|
EXHIBIT
INDEX
Exhibit
No
.
|
|
Exhibit
Description
|
|
|
|
1.1*
|
|
Underwriting
Agreement, dated as of January 19, 2017, by and between Amedica Corporation and Maxim Group LLC
|
|
|
|
4.1*
|
|
Form
of Warrant
|
|
|
|
5.1*
|
|
Opinion
of Dorsey & Whitney LLP
|
|
|
|
23.1*
|
|
Consent
of Dorsey & Whitney LLP (included in Exhibit 5.1)
|
|
|
|
99.1*
|
|
Press
Release dated January 19, 2017
|
*
Filed herewith
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024